Long-term drug treatment in multiple sclerosis: safety success and concerns

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients

(2020) Peter Alping et al.   ANNALS OF NEUROLOGY

Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis

(2020) Pengcheng Zhang et al.   BONE MARROW TRANSPLANTATION

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

(2020) Robert T. Naismith et al.   CNS DRUGS

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry

(2020) Kerstin Hellwig et al.   JOURNAL OF NEUROLOGY

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective

(2020) Jakimovski et al.   Vaccines

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

(2020) Petra Dirks et al.   BMC Neurology

Sex‐Specific Differences in Life Span Brain Volumes in Multiple Sclerosis

(2020) Dejan Jakimovski et al.   JOURNAL OF NEUROIMAGING

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

(2020) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

(2020) Helmut Butzkueven et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective

(2020) Gauruv Bose et al.   Multiple Sclerosis Journal

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP)

(2020) Helmut Butzkueven et al.   Multiple Sclerosis Journal

Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis

(2020) Simon Thebault et al.   Annals of Clinical and Translational Neurology

Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy

(2020) Marjo Nylund et al.   Multiple Sclerosis and Related Disorders

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

(2020) David Baker et al.   Multiple Sclerosis and Related Disorders

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis

(2019) Richard K. Burt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study

(2019) Hans-Peter Hartung et al.   JOURNAL OF NEUROLOGY

Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis

(2019) Lidia Stork et al.   Multiple Sclerosis Journal

Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study

(2019) Robert Zivadinov et al.   Journal of Comparative Effectiveness Research

HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab

(2019) M. I. R. Dudek et al.   JOURNAL OF NEUROLOGY

Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy

(2019) Simonetta Gerevini et al.   Multiple Sclerosis Journal

Epidemiology and treatment of multiple sclerosis in elderly populations

(2019) Caila B. Vaughn et al.   Nature Reviews Neurology

Fulminant Hepatitis Associated With Echovirus 25 During Treatment With Ocrelizumab for Multiple Sclerosis

(2019) Laura Ambra Nicolini et al.   JAMA Neurology

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

(2019) Giancarlo Comi et al.   Multiple Sclerosis and Related Disorders

Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis

(2019) Rachael McCool et al.   Multiple Sclerosis and Related Disorders

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study

(2019) Aaron E. Miller et al.   Multiple Sclerosis and Related Disorders

Coagulation Pathways in Neurological Diseases: Multiple Sclerosis

(2019) Nicole Ziliotto et al.   Frontiers in Neurology

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study

(2019) Robert Zivadinov et al.   Journal of Clinical Medicine

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence

(2019) Martin Diebold et al.   Multiple Sclerosis Journal

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

(2019) Basil Sharrack et al.   BONE MARROW TRANSPLANTATION

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study

(2019) Dejan Jakimovski et al.   Multiple Sclerosis Journal

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

(2019) Giancarlo Comi et al.   Multiple Sclerosis Journal

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

(2019) Bart Van Wijmeersch et al.   Multiple Sclerosis Journal

Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab

(2019) Clara Aguirre et al.   Multiple Sclerosis and Related Disorders

The 5-year Tysabri Global Observational Program in Safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis

(2019) John Foley et al.   Multiple Sclerosis and Related Disorders

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)

(2018) M. Mikulska et al.   CLINICAL MICROBIOLOGY AND INFECTION

An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis

(2018) Caila Vaughn et al.   CNS DRUGS

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis

(2018) Antonio Riccardo Buonomo et al.   Expert Opinion On Drug Safety

Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells

(2018) Tania Carmenate et al.   JOURNAL OF IMMUNOLOGY

Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations

(2018) Virginia Devonshire et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

(2018) Raju Kapoor et al.   LANCET NEUROLOGY

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study

(2018) Stephen W Reddel et al.   Multiple Sclerosis Journal

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

(2018) Kaarina Kowalec et al.   NATURE GENETICS

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance

(2018) Paolo A. Muraro et al.   NEUROLOGY

Progressive multifocal leukoencephalopathy after fingolimod treatment

(2018) Joseph R. Berger et al.   NEUROLOGY

Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity

(2018) Michael D. Kornberg et al.   SCIENCE

The Evolving Mechanisms of Action of Glatiramer Acetate

(2018) Thomas Prod'homme et al.   Cold Spring Harbor Perspectives in Medicine

Alemtuzumab as Treatment for Multiple Sclerosis

(2018) Serafeim Katsavos et al.   Cold Spring Harbor Perspectives in Medicine

Interferon β for Multiple Sclerosis

(2018) Dejan Jakimovski et al.   Cold Spring Harbor Perspectives in Medicine

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study

(2018) Stephen W Reddel et al.   Multiple Sclerosis Journal

Teeth loss after teriflunomide treatment: Casual or causal? A short case series

(2018) Veria Vacchiano et al.   Multiple Sclerosis and Related Disorders

72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension

(2018) Hirofumi Ochi et al.   ADVANCES IN THERAPY

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study

(2018) D. Jakimovski et al.   EUROPEAN JOURNAL OF NEUROLOGY

Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

(2018) Eva Rosa Petersen et al.   Multiple Sclerosis Journal

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

(2018) Sibyl Wray et al.   Multiple Sclerosis Journal

Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis

(2018) Fangfang Ge et al.   NEUROLOGICAL SCIENCES

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis

(2018) Stuart Cook et al.   Multiple Sclerosis and Related Disorders

Ocrelizumab: a B-cell depleting therapy for multiple sclerosis

(2017) Dejan Jakimovski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine

(2017) Karl B. Alstadhaug et al.   JOURNAL OF CLINICAL VIROLOGY

Long-term follow-up more than 10 years after HSCT: a monocentric experience

(2017) Jessica Frau et al.   JOURNAL OF NEUROLOGY

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

(2017) Robbert-Jan Gieselbach et al.   JOURNAL OF NEUROLOGY

Two decades of glatiramer acetate: From initial discovery to the current development of generics

(2017) Bianca Weinstock-Guttman et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

(2017) Pei-Ran Ho et al.   LANCET NEUROLOGY

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study

(2017) Chiara Zecca et al.   Multiple Sclerosis Journal

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients

(2017) Cyra E Leurs et al.   Multiple Sclerosis Journal

Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

(2017) Zoé LE van Kempen et al.   Multiple Sclerosis Journal

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

(2017) Paolo A. Muraro et al.   Nature Reviews Neurology

Alemtuzumab CARE-MS I 5-year follow-up

(2017) Eva Havrdova et al.   NEUROLOGY

Evaluating the safety of β-interferons in MS

(2017) Hilda J.I. de Jong et al.   NEUROLOGY

PML in a person with multiple sclerosis

(2017) Lorena Lorefice et al.   NEUROLOGY

Alemtuzumab CARE-MS II 5-year follow-up

(2017) Alasdair J. Coles et al.   NEUROLOGY

Cladribine to Treat Relapsing Forms of Multiple Sclerosis

(2017) Gavin Giovannoni   Neurotherapeutics

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

(2017) David Baker et al.   JAMA Neurology

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

(2017) Paolo A. Muraro et al.   JAMA Neurology

Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study

(2017) Chiara Zecca et al.   Multiple Sclerosis Journal

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients

(2017) Cyra E Leurs et al.   Multiple Sclerosis Journal

Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

(2017) Zoé LE van Kempen et al.   Multiple Sclerosis Journal

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβ treatment

(2017) Leila Alba Palé et al.   Multiple Sclerosis and Related Disorders

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study

(2017) Patricia K. Coyle et al.   Multiple Sclerosis and Related Disorders

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years

(2017) Fred D. Lublin et al.   Multiple Sclerosis and Related Disorders

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

(2017) Ann Marie Weideman et al.   Frontiers in Neurology

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

(2016) James G. Krueger et al.   ADVANCES IN THERAPY

Long-term evolution of multiple sclerosis disability in the treatment era

(2016) et al.   ANNALS OF NEUROLOGY

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

(2016) Ralf Gold et al.   BMC Neurology

Use of natalizumab in multiple sclerosis: current perspectives

(2016) Sirin Gandhi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients

(2016) Tjalf Ziemssen et al.   JOURNAL OF NEUROLOGY

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation

(2016) Bianca Weinstock-Guttman et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Extended interval dosing of natalizumab in multiple sclerosis

(2016) L Zhovtis Ryerson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

(2016) Ralf Gold et al.   Multiple Sclerosis Journal

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study

(2016) Omar Khan et al.   Multiple Sclerosis Journal

Cutaneous adverse events in multiple sclerosis patients treated with daclizumab

(2016) Irene Cortese et al.   NEUROLOGY

Long-term safety and efficacy of teriflunomide

(2016) Paul O'Connor et al.   NEUROLOGY

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

(2016) Ralf Gold et al.   Multiple Sclerosis Journal

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study

(2016) Omar Khan et al.   Multiple Sclerosis Journal

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

(2016) Giancarlo Comi et al.   Multiple Sclerosis and Related Disorders

Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies

(2016) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Seroepidemiology of Human Polyomaviruses in a US Population

(2015) Anala Gossai et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis

(2015) Athina Papadopoulou et al.   Expert Opinion On Drug Safety

Body mass index influence interferon-beta treatment response in multiple sclerosis

(2015) Silje Stokke Kvistad et al.   JOURNAL OF NEUROIMMUNOLOGY

Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy

(2015) Helmar C. Lehmann et al.   JOURNAL OF NEUROLOGY

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

(2015) Jeffrey A Cohen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis

(2015) Rebekka Kohlmann et al.   Multiple Sclerosis Journal

Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study

(2015) Daniela Curro’ et al.   Multiple Sclerosis Journal

Switching from natalizumab to fingolimod

(2015) Ludwig Kappos et al.   NEUROLOGY

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

(2015) D. H. Miller et al.   NEUROLOGY

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adherence to Glatiramer Acetate 40 Mg Versus Oral Disease-Modifying Therapies for Multiple Sclerosis

(2015) R Halpern et al.   VALUE IN HEALTH

Varicella-Zoster Virus Infections in Patients Treated With Fingolimod

(2015) Ann M. Arvin et al.   JAMA Neurology

Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod

(2015) Lutz Achtnichts et al.   JAMA Neurology

Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis

(2015) Jeffrey Cohen et al.   JAMA Neurology

Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis

(2015) Rebekka Kohlmann et al.   Multiple Sclerosis Journal

Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study

(2015) Daniela Curro’ et al.   Multiple Sclerosis Journal

Risk tolerance to MS therapies: Survey results from the NARCOMS registry

(2015) Robert J. Fox et al.   Multiple Sclerosis and Related Disorders

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis

(2015) Jerry S. Wolinsky et al.   Multiple Sclerosis and Related Disorders

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

(2014) Kaarina Kowalec et al.   Expert Opinion On Drug Safety

Drug safety evaluation of alemtuzumab for multiple sclerosis

(2014) Mark Willis et al.   Expert Opinion On Drug Safety

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

(2014) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

(2014) Gavin Giovannoni et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

(2014) Thomas P Leist et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

(2014) P. O'Connor et al.   NEUROLOGY

Thrombotic Microangiopathy Associated with Interferon Beta

(2014) David Hunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis

(2014) Sara J. Ireland et al.   JAMA Neurology

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

(2014) John P. DiMarco et al.   Multiple Sclerosis and Related Disorders

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

(2014) J. Theodore Phillips et al.   Multiple Sclerosis and Related Disorders

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

(2013) Omar Khan et al.   ANNALS OF NEUROLOGY

Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series

(2013) J. D. Rosenberg et al.   BLOOD

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

(2013) P. S. Rommer et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

(2013) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

(2013) G Francis et al.   Multiple Sclerosis Journal

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis

(2013) Marco A. Zarbin et al.   OPHTHALMOLOGY

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis

(2013) Anthony T. Reder et al.   Multiple Sclerosis and Related Disorders

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

(2012) Giancarlo Comi et al.   JOURNAL OF NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

(2012) Virginia Devonshire et al.   LANCET NEUROLOGY

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

(2012) Giancarlo Comi et al.   Multiple Sclerosis Journal

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

(2012) Anke Vennegoor et al.   Multiple Sclerosis Journal

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

(2012) Christian Confavreux et al.   Multiple Sclerosis Journal

Teriflunomide added to interferon-  in relapsing multiple sclerosis: A randomized phase II trial

(2012) M. S. Freedman et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Engagement of S1P1-degradative mechanisms leads to vascular leak in mice

(2011) Myat Lin Oo et al.   JOURNAL OF CLINICAL INVESTIGATION

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-1a: analysis of data from clinical trial and post-marketing surveillance settings

(2011) Magnhild Sandberg-Wollheim et al.   Multiple Sclerosis Journal

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience

(2010) Eva Krasulová et al.   Multiple Sclerosis Journal

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

(2010) Christoph Heesen et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells

(2009) P. Kivisakk et al.   NEUROLOGY

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study

(2009) A. D. Goodman et al.   NEUROLOGY

Interferon-  mechanisms of action in multiple sclerosis

(2009) S. Dhib-Jalbut et al.   NEUROLOGY

Leflunomide-Associated Progressive Multifocal Leukoencephalopathy

(2008) Megan Rahmlow et al.   ARCHIVES OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE